Xbrane Biopharma Valuation Multiples

Xbrane Biopharma Overview

About Xbrane Biopharma

Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. Xbrane’s product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration.

Founded

2008

HQ

Employees

65

Website

xbrane.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $17M

EBITDA: ($4M)

EV

$23M

Valuation Multiples

Multiples.vc

Start free trial

Xbrane Biopharma Financials

Xbrane Biopharma reported last 12-month revenue of $17M and negative EBITDA of ($4M).

In the same LTM period, Xbrane Biopharma generated ($4M) in EBITDA losses and $9M in net income.

Xbrane Biopharma P&L

In the most recent fiscal year, Xbrane Biopharma reported revenue of $17M and EBITDA of ($1M).

Xbrane Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Xbrane Biopharma Stock Performance

Xbrane Biopharma has current market cap of $26M, and enterprise value of $23M.

Xbrane Biopharma's stock price is $1.25.

Xbrane Biopharma Valuation Multiples

Xbrane Biopharma trades at 1.4x EV/Revenue multiple, and (5.7x) EV/EBITDA.

Xbrane Biopharma Financial Valuation Multiples

As of April 18, 2026, Xbrane Biopharma has market cap of $26M and EV of $23M.

Equity research analysts estimate Xbrane Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Xbrane Biopharma has a P/E ratio of 3.0x.

Xbrane Biopharma Margins & Growth Rates

Xbrane Biopharma's revenue in the last 12 month grew by 9%.

Xbrane Biopharma's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.

Xbrane Biopharma's rule of 40 is (11%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Xbrane Biopharma's rule of X is (12%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Xbrane Biopharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Xbrane Biopharma M&A Activity

Xbrane Biopharma acquired XXX companies to date.

Last acquisition by Xbrane Biopharma was on XXXXXXXX, XXXXX. Xbrane Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Xbrane Biopharma Investment Activity

Xbrane Biopharma invested in XXX companies to date.

Xbrane Biopharma made its latest investment on XXXXXXXX, XXXXX. Xbrane Biopharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).